# Aptevo Therapeutics (APVO) — News

APVO · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/apvo/news

## Recent headlines

- [Aptevio Therapeutics - Expects to enter ind-enabling studies for apvo451 in 1H2027 - SEC filing](https://www.ainvest.com/news/aptevio-therapeutics-expects-enter-ind-enabling-studies-apvo451-1h2027-sec-filing-2609) — AInvest Wire, Sep 24, 2026
  Aptevio Therapeutics Inc. has disclosed in a recent SEC filing that it anticipates initiating investigational new drug (IND)-enabling studies for its candidate, apvo451, during the first half of 2027[1]. The announcement outlines the company’s next major milestone in its drug development pipeline,…
- [Aptevio Therapeutics shares down 16.2% premarket after co announces leukemia drug study update](https://www.ainvest.com/news/aptevio-therapeutics-shares-16-2-premarket-announces-leukemia-drug-study-update-2609) — AInvest Wire, Sep 3, 2026
  Aptevo Therapeutics Inc. (APVO) shares fell 16.2% in premarket trading following the company’s announcement of an update regarding its clinical trial for Mipletamig, a drug candidate targeting acute myeloid leukemia (AML). The update comes after earlier positive results from a Phase 1b/2 trial,…
- [Aptevio Therapeutics - Regulatory interaction planned for 1H27 for Mipletamig in frontline AML - SEC filing](https://www.ainvest.com/news/aptevio-therapeutics-regulatory-interaction-planned-1h27-mipletamig-frontline-aml-sec-filing-2609) — AInvest Wire, Sep 3, 2026
- [Aptevio Therapeutics - Rainier study dose optimization phase expected to complete by year-end - SEC filing](https://www.ainvest.com/news/aptevio-therapeutics-rainier-study-dose-optimization-phase-expected-complete-year-sec-filing-2609) — AInvest Wire, Sep 3, 2026
- [Aptevio Therapeutics - Reports 93% clinical benefit rate with mipletamig triplet in TP53-mutated AML - SEC filing](https://www.ainvest.com/news/aptevio-therapeutics-reports-93-clinical-benefit-rate-mipletamig-triplet-tp53-mutated-aml-sec-filing-2609) — AInvest Wire, Sep 3, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).